Dosing has begun in a clinical trial evaluating ARO-MMP7, Arrowhead Pharmaceuticals’ investigational RNA interference (RNAi) therapy for idiopathic pulmonary fibrosis (IPF). Expecting to enroll up to 56 healthy volunteers and 21 adults with IPF, the Phase 1/2a trial (NCT05537025) — dubbed AROMMP7-1001 — will evaluate the therapy’s…
IPF trial of RNAi therapy starts dosing patients, healthy volunteers
Strados Labs is teaming up with Boehringer Ingelheim to conduct a pilot study leveraging its RESP Biosensor, a first-of-its-kind device designed to remotely monitor key changes in lung sounds, cough, and other respiratory issues in people with idiopathic pulmonary fibrosis (IPF) and other lung disorders. In Boehringer…
There are certain moments in our lives when a single event becomes indelibly etched into our memory. And the significance of such moments is dictated by each of us. Think about that for a minute. What moments are etched into your memory? Have you dealt with the loss of a…
The highest tested dose of bexotegrast, an anti-fibrotic treatment candidate from Pliant Therapeutics, was found to best — and safely — improve lung function in people with idiopathic pulmonary fibrosis (IPF), outperforming all lower doses in a Phase 2a trial. Three-month data from the INTEGRIS-IPF trial (NCT04396756)…
The Pulmonary Fibrosis Foundation (PFF) is set to present the 13th edition of “Broadway Belts for PFF!” — an annual glitzy affair that has become the nonprofit’s single-largest fundraiser — on March 6. The gala, which also seeks to heighten awareness of pulmonary fibrosis (PF), will take place…
Minutes after I’m wheeled into the operating room, everyone stops — a timeout. Lying on my back with an awesome view of the ceiling, the calm and quiet of the room are very noticeable. I’d been connected to various leads, used to monitor everything from my heart rhythm to my…
KIN001, an experimental oral treatment of idiopathic pulmonary fibrosis (IPF), was more effective than Esbriet (pirfenidone) at easing lung fibrosis in a mouse model of the disease, its developer, Kinarus Therapeutics, reported. When KIN001 was given with Esbriet, an approved treatment, the reduction in fibrosis was even greater than…
The Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis (PF) has enrolled its last patient. Recruitment finished sooner than anticipated, according to INOpulse developer Bellerophon Therapeutics. Top-line results are expected later this year and it’s hoped they will support efforts on…
Shortly after I was diagnosed with idiopathic pulmonary fibrosis (IPF), I was on a walk and spotted a leaf in the shape of a heart. For some reason, the beauty of it struck me. It was a sign; nature had left me a message. I collected the leaf and…
New Year’s resolutions are an annual tradition for many of us. We make promises to ourselves to do something better in the year. But this year, I’ve decided to do something different: Instead of resolutions, I plan to make new memories. Why make resolutions I know I can’t keep? After…
